Mutations in FYN kinase pose potential diagnostic marker, therapeutic target for adult T-cell lymphoma
- Summary
- Adolfo Ferrando, M.D., Ph.D.
- Technology Benefits
- FYN mutations may serve as diagnostic and prognostic markers for T-cell lymphoma. Represents novel therapeutic target for adult peripheral T-cell lymphoma. Patients that may respond to treatment are identifiable by screening for FYN mutations.FYN inhibitors would selectively target constitutively active disease pathway, potentially increasing treatment efficacy. FYN inhibitors may permit reduced dosing of other chemotherapeutics, reducing the adverse side effects. Patent information:Patent Pending
- Technology Application
- Diagnostic marker for patients with adult peripheral T-cell lymphomas.Prognostic marker for patients with adult peripheral T-cell lymphomas.Development of potent FYN inhibitors as a potential therapy for T-cell lymphomas. Biomarker of sensitivity to FYN inhibitor therapy.
- Detailed Technology Description
- Adolfo Ferrando, M.D., Ph.D.
- *Abstract
-
None
- *Inquiry
- Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU13222
- *Principal Investigator
-
- Country/Region
- USA
For more information, please click Here
